Form 4: Syndax Director Jarrett Awarded 24,000 Restricted Stock Units

Syndax Pharmaceuticals Director Jennifer Jarrett received an award of 24,000 Restricted Stock Units, set to vest one year from the grant date.

Summary

• Jennifer Jarrett, a Director of Syndax Pharmaceuticals Inc. (SNDX), was granted 24,000 shares of Common Stock in the form of Restricted Stock Units (RSUs).
• The transaction date for this award is February 4, 2026, with a price of $0 per share, indicating a grant.
• These RSUs will vest one year from the grant date.
• The shares underlying these RSUs will not be delivered, transferred, or sold until the earlier of separation from service, death, disability, or a change in control.
• Following this transaction, Jennifer Jarrett beneficially owns 114,000 shares directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, as it represents routine director compensation that fosters alignment with shareholder interests without introducing new material financial information.

Positives

• The RSU award aligns the director's interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• The vesting schedule acts as a retention incentive, encouraging the director to remain with the company for at least one year.

Negatives

• The issuance of new shares for RSU awards can lead to minor dilution for existing shareholders, although this is a standard practice for equity compensation.

Risks

• The value of the RSU award is subject to the future market price of Syndax Pharmaceuticals Inc. common stock, meaning the actual value realized by the director could be lower than the grant-date value if the stock price declines.
• The director risks forfeiture of the unvested RSUs if conditions for vesting (e.g., continued service) are not met.

Future Outlook

The filing indicates a future vesting event for the awarded Restricted Stock Units, scheduled for one year from the grant date of February 4, 2026, contingent on continued service or other specified conditions.

Industry Context

StockSavvy.ai notes that equity-based compensation, such as Restricted Stock Units, is a prevalent practice in the biotechnology and pharmaceutical sectors for compensating directors and executives. This method is widely adopted to align the interests of leadership with long-term shareholder value creation, particularly in industries with significant research and development cycles and long-term strategic goals.

Comparison to Industry Standards

• The grant of Restricted Stock Units to a director is consistent with common compensation practices observed across the biotechnology and broader public company landscape.
• The vesting schedule of one year is a typical period for such awards, balancing retention with performance incentives.

Stakeholder Impact

• Shareholders: The RSU award promotes alignment between the director's financial interests and the company's stock performance, potentially benefiting long-term shareholder value.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The 24,000 Restricted Stock Units are scheduled to vest one year from the grant date of February 4, 2026.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation award to a director and does not contain new fundamental information that would significantly alter the investment thesis for Syndax Pharmaceuticals Inc. It is a standard corporate governance practice aimed at aligning interests, and as such, does not warrant a change in investment recommendation based solely on this disclosure.

Keywords

Syndax Pharmaceuticals, SNDX, Restricted Stock Units, RSU award, Director compensation, Insider transaction, Equity compensation, Form 4